PL2969099T3 - Usuwanie wypłukanego ligandu do oczyszczania na zasadzie powinowactwa - Google Patents

Usuwanie wypłukanego ligandu do oczyszczania na zasadzie powinowactwa

Info

Publication number
PL2969099T3
PL2969099T3 PL14714890T PL14714890T PL2969099T3 PL 2969099 T3 PL2969099 T3 PL 2969099T3 PL 14714890 T PL14714890 T PL 14714890T PL 14714890 T PL14714890 T PL 14714890T PL 2969099 T3 PL2969099 T3 PL 2969099T3
Authority
PL
Poland
Prior art keywords
leaked
removal
affinity purification
purification ligand
ligand
Prior art date
Application number
PL14714890T
Other languages
English (en)
Other versions
PL2969099T5 (pl
Inventor
Samuel Ray TREJO
Robert Perry BRAKE
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2969099(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of PL2969099T3 publication Critical patent/PL2969099T3/pl
Publication of PL2969099T5 publication Critical patent/PL2969099T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL14714890T 2013-03-14 2014-03-11 Usuwanie wypłukanego ligandu do oczyszczania na zasadzie powinowactwa PL2969099T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14
EP14714890.2A EP2969099B2 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand
PCT/US2014/023682 WO2014159441A1 (en) 2013-03-14 2014-03-11 Removal of leaked affinity purification ligand

Publications (2)

Publication Number Publication Date
PL2969099T3 true PL2969099T3 (pl) 2018-10-31
PL2969099T5 PL2969099T5 (pl) 2022-06-13

Family

ID=50424772

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14714890T PL2969099T5 (pl) 2013-03-14 2014-03-11 Usuwanie wypłukanego ligandu do oczyszczania na zasadzie powinowactwa
PL18168494.5T PL3395423T3 (pl) 2013-03-14 2014-03-11 Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18168494.5T PL3395423T3 (pl) 2013-03-14 2014-03-11 Usuwanie wypłukanych ligandów do oczyszczania na zasadzie powinowactwa

Country Status (17)

Country Link
US (3) US20160024144A1 (pl)
EP (3) EP3395423B1 (pl)
JP (1) JP6457479B2 (pl)
AU (1) AU2014240596B2 (pl)
CA (1) CA2904411A1 (pl)
CY (1) CY1120353T1 (pl)
DK (2) DK2969099T4 (pl)
ES (2) ES2674697T5 (pl)
FI (1) FI3395423T3 (pl)
HU (2) HUE064450T2 (pl)
LT (2) LT3395423T (pl)
MX (2) MX391507B (pl)
PL (2) PL2969099T5 (pl)
PT (2) PT3395423T (pl)
SI (2) SI2969099T2 (pl)
TR (1) TR201809050T4 (pl)
WO (1) WO2014159441A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE064450T2 (hu) 2013-03-14 2024-03-28 Amgen Inc Kiszivárgott affinitás tisztító ligandum eltávolítása
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
AU2015273049B2 (en) * 2014-06-13 2019-11-14 Lupin Limited Process for the purification of TNFR:Fc fusion protein
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
US20200283472A1 (en) * 2016-03-29 2020-09-10 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
WO2018146067A1 (en) 2017-02-09 2018-08-16 Bracco Suisse Sa Process for the purification of soluble psgl-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーション 可溶性オリゴマー蛋白質の調製法
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
KR100510234B1 (ko) 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
EP0906357B1 (de) 1996-06-21 2001-08-08 MERCK PATENT GmbH Polymere sorbentien auf basis polymerisationsfähiger derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998058253A1 (de) 1997-06-18 1998-12-23 Merck Patent Gmbh Verwendung monolithischer sorbentien für präparative chromatographische trennverfahren
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
MXPA04006053A (es) * 2001-12-21 2005-03-31 Immunex Corp Metodos para purificacion de proteina.
ES2797480T3 (es) * 2005-03-11 2020-12-02 Wyeth Llc Un procedimiento de cromatografía de reparto débil
SI2078071T1 (sl) * 2006-11-08 2015-05-29 Wyeth Llc Racionalno zasnovana gojišča za celično kulturo
AU2010260476A1 (en) * 2009-03-11 2011-10-13 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
JP5980782B2 (ja) * 2010-07-30 2016-08-31 ファイザー・インク タンパク質のタンデム精製
WO2012176158A1 (en) * 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
AU2012282960A1 (en) * 2011-07-08 2014-01-16 Merck Sharp & Dohme Corp. Method for purifying Fc-fusion protein
EP2773671B1 (en) * 2011-11-04 2021-09-15 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
HUE064450T2 (hu) 2013-03-14 2024-03-28 Amgen Inc Kiszivárgott affinitás tisztító ligandum eltávolítása

Also Published As

Publication number Publication date
FI3395423T3 (fi) 2023-11-02
DK2969099T4 (da) 2022-03-14
PT3395423T (pt) 2023-11-14
SI2969099T2 (sl) 2022-04-29
HK1220159A1 (en) 2017-04-28
LT2969099T (lt) 2018-09-10
DK2969099T3 (en) 2018-07-09
EP2969099A1 (en) 2016-01-20
EP2969099B1 (en) 2018-04-25
EP2969099B2 (en) 2021-12-22
SI3395423T1 (sl) 2023-12-29
JP6457479B2 (ja) 2019-01-23
JP2016513643A (ja) 2016-05-16
EP3395423A1 (en) 2018-10-31
CA2904411A1 (en) 2014-10-02
US11192919B2 (en) 2021-12-07
AU2014240596A1 (en) 2015-09-24
CY1120353T1 (el) 2019-07-10
DK3395423T3 (da) 2023-11-20
US20220144886A1 (en) 2022-05-12
EP4026596A1 (en) 2022-07-13
US11492372B2 (en) 2022-11-08
PL3395423T3 (pl) 2024-03-18
US20160024144A1 (en) 2016-01-28
ES2674697T5 (es) 2022-04-19
HUE038565T2 (hu) 2018-10-29
SI2969099T1 (sl) 2018-09-28
MX2015011994A (es) 2015-12-01
HUE064450T2 (hu) 2024-03-28
WO2014159441A1 (en) 2014-10-02
PL2969099T5 (pl) 2022-06-13
AU2014240596B2 (en) 2018-09-27
MX365501B (es) 2019-06-05
LT3395423T (lt) 2023-12-11
PT2969099T (pt) 2018-07-05
MX2019006568A (es) 2019-08-22
MX391507B (es) 2025-03-21
TR201809050T4 (tr) 2018-07-23
EP3395423B1 (en) 2023-09-20
ES2674697T3 (es) 2018-07-03
ES2964601T3 (es) 2024-04-08
US20190085021A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
IL240718A0 (en) filtering
IL244095A0 (en) Modulators of complement factor b
GB201314217D0 (en) Coolant purification
PL3263994T3 (pl) Filtry
PL3068854T5 (pl) Usuwanie niepożądanych składników propanolu
SG11201603028SA (en) Purification of proteins
GB201303016D0 (en) Filter
GB2517985B (en) Sheaf-based fluid filter
HUE038565T2 (hu) Kiszivárgott affinitás tisztító ligandumok eltávolítása
GB201303024D0 (en) Filter
ZA201603797B (en) Novel purification processes
GB201303013D0 (en) Filter
GB201310928D0 (en) New Processes
GB201303018D0 (en) Filter
GB201303027D0 (en) Filter
GB201303033D0 (en) Filter
GB201303636D0 (en) Chamber fluid removal system
GB201303019D0 (en) Filter
GB2515553B (en) Coolant purification
PL3063156T3 (pl) Sposób oczyszczania lecytyny
GB201314581D0 (en) Purification
GB201303030D0 (en) Filter
GB2512032B (en) Filter
GB201315128D0 (en) Gas Filter
GB201318565D0 (en) New processes